Acinic cell carcinoma is an indolent form of invasive breast cancer, whereas microglandular adenosis has been shown to be a neoplastic proliferation. Both entities display a triple-negative phenotype, and may give rise to and display somatic genomic alterations typical of high-grade triple-negative breast cancers. Here we report on a comparison of previously published data on eight carcinoma-associated microglandular adenosis and eight acinic cell carcinomas subjected to targeted massively parallel sequencing targeting all exons of 236 genes recurrently mutated in breast cancer and/or DNA repair-related. Somatic mutations, insertions/ deletions, and copy number alterations were detected using state-of-the-art bioinformatic algorithms. All cases were of triple-negative phenotype. A median of 4.5 (1-13) and 4.0 (1-7) non-synonymous somatic mutations per carcinoma-associated microglandular adenosis and acinic cell carcinoma were identified, respectively. TP53 was the sole highly recurrently mutated gene (75% in microglandular adenosis versus 88% in acinic cell carcinomas), and TP53 mutations were consistently coupled with loss of heterozygosity of the wild-type allele. Additional somatic mutations shared by both groups included those in BRCA1, PIK3CA, and INPP4B. Recurrent (n=2) somatic mutations restricted to microglandular adenosis or acinic cell carcinomas included those affecting PTEN and MED12 or ERBB4, respectively. No significant differences in the repertoire of somatic mutations were detected between microglandular adenosis and acinic cell carcinomas, and between this group of lesions and 77 triple-negative carcinomas from The Cancer Genome Atlas. Microglandular adenosis and acinic cell carcinomas, however, were genetically distinct from estrogen receptor-positive and/or HER2-positive breast cancers from The Cancer Genome Atlas. Our findings support the contention that microglandular adenosis and acinic cell carcinoma are part of the same spectrum of lesions harboring frequent TP53 somatic mutations, and likely represent low-grade forms of triple-negative disease with no/minimal metastatic potential, of which a subset has the potential to progress to high-grade triple-negative breast cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221420PMC
http://dx.doi.org/10.1038/modpathol.2016.161DOI Listing

Publication Analysis

Top Keywords

microglandular adenosis
36
acinic cell
36
adenosis acinic
28
cell carcinomas
24
somatic mutations
24
triple-negative breast
12
cell carcinoma
12
breast cancer
12
microglandular
9
adenosis
9

Similar Publications

Article Synopsis
  • * Diagnosis relies on the presence of specific granular cytoplasm and markers indicating serous acinar differentiation, and despite being seen as a low-grade form of triple-negative breast cancer (TNBC), over a quarter of patients face poor outcomes.
  • * The text reviews current literature on AciCC, proposing it may develop from microglandular adenosis (MGA), and aims to clarify its origins, molecular traits, and treatment options, as this has not been thoroughly summarized before.
View Article and Find Full Text PDF

Background: Mammography has become an invaluable tool for diagnosing breast lesions and detecting early breast cancer in women of 35 years and above.

Aims: To correlate the mammography Breast Imaging Reporting and Data System (BI-RADS) categories with the histology in breast lesions and to determine the predictive values, sensitivity, specificity and accuracy of mammography.

Patients And Method: This was a one- year prospective study carried out from March 2015 to February 2016.

View Article and Find Full Text PDF

This systematic review and meta-analysis study aimed to determine the total capacity of contrast-enhanced ultrasound (CEUS) in the differential diagnosis of breast lesions and breast cancer. For collecting papers, four groups of keywords were searched in five databases. The required information was extracted from the selected papers.

View Article and Find Full Text PDF
Article Synopsis
  • - Danazol is a synthetic progestin with androgenic effects approved for treating conditions like endometriosis and is increasingly used for menstrual suppression in transgender and nonbinary individuals, despite a lack of research on its efficacy in this population
  • - A retrospective study reviewed the experiences of transgender patients using danazol for menstrual suppression at two healthcare centers between 2000 and 2022, comparing those who did and did not use the treatment
  • - Results indicated that most patients remained on danazol during follow-ups, with improvements in gender dysphoria, pelvic pain, and menstrual symptoms, and most achieved amenorrhea, suggesting its potential as an effective option for menstrual suppression in this demographic
View Article and Find Full Text PDF

Cancer is the leading cause of death worldwide. The World Health Organization (WHO) estimates that 10 million fatalities occurred in 2023. Breast cancer (BC) ranked first among malignancies with 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!